Brokers Offer Predictions for RVPH Q1 Earnings

Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) – Equities researchers at Roth Capital issued their Q1 2026 EPS estimates for Reviva Pharmaceuticals in a report issued on Friday, April 4th. Roth Capital analyst B. Pachaiyappan forecasts that the company will earn ($0.16) per share for the quarter. Roth Capital has a “Strong-Buy” rating on the stock. The consensus estimate for Reviva Pharmaceuticals’ current full-year earnings is ($0.97) per share. Roth Capital also issued estimates for Reviva Pharmaceuticals’ Q2 2026 earnings at ($0.16) EPS, Q3 2026 earnings at ($0.17) EPS and Q4 2026 earnings at ($0.19) EPS.

RVPH has been the topic of several other reports. Maxim Group raised Reviva Pharmaceuticals from a “hold” rating to a “buy” rating and set a $7.00 price target on the stock in a research report on Friday, January 10th. HC Wainwright dropped their target price on Reviva Pharmaceuticals from $14.00 to $11.00 and set a “buy” rating on the stock in a report on Wednesday, January 22nd. Roth Mkm assumed coverage on shares of Reviva Pharmaceuticals in a report on Friday, January 10th. They set a “buy” rating and a $7.00 price target for the company. Finally, D. Boral Capital lowered their price objective on shares of Reviva Pharmaceuticals from $15.00 to $8.00 and set a “buy” rating on the stock in a research report on Tuesday, April 1st. Five analysts have rated the stock with a buy rating and two have given a strong buy rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Buy” and an average target price of $10.00.

Reviva Pharmaceuticals Stock Up 13.2 %

RVPH opened at $0.60 on Monday. The firm has a market capitalization of $20.06 million, a P/E ratio of -0.54 and a beta of 0.05. The stock has a fifty day moving average of $1.38 and a 200-day moving average of $1.45. Reviva Pharmaceuticals has a 12-month low of $0.49 and a 12-month high of $4.28.

Reviva Pharmaceuticals (NASDAQ:RVPH) last posted its quarterly earnings data on Monday, March 31st. The company reported ($0.15) EPS for the quarter, topping analysts’ consensus estimates of ($0.22) by $0.07.

Institutional Investors Weigh In On Reviva Pharmaceuticals

Several institutional investors have recently made changes to their positions in RVPH. Geode Capital Management LLC increased its holdings in shares of Reviva Pharmaceuticals by 17.9% during the 3rd quarter. Geode Capital Management LLC now owns 278,496 shares of the company’s stock valued at $401,000 after acquiring an additional 42,376 shares during the last quarter. EMC Capital Management boosted its position in Reviva Pharmaceuticals by 142.0% during the fourth quarter. EMC Capital Management now owns 44,535 shares of the company’s stock worth $81,000 after purchasing an additional 26,134 shares during the period. Drive Wealth Management LLC acquired a new position in Reviva Pharmaceuticals during the fourth quarter valued at approximately $36,000. Ameriprise Financial Inc. acquired a new position in Reviva Pharmaceuticals during the fourth quarter valued at approximately $84,000. Finally, Tang Capital Management LLC bought a new position in shares of Reviva Pharmaceuticals in the fourth quarter valued at approximately $308,000. 63.18% of the stock is currently owned by institutional investors and hedge funds.

About Reviva Pharmaceuticals

Reviva Pharmaceuticals Holdings, Inc, a biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, inflammatory, and cardiometabolic diseases. The company's lead product candidate comprises brilaroxazine (RP5063) for the treatment of various neuropsychiatric indications, including schizophrenia, bipolar disorder, major depressive disorder, attentiondeficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia and Alzheimer's disease, and Parkinson's disease psychosis; in clinical development respiratory indications, such as pulmonary arterial hypertension and idiopathic pulmonary fibrosis; and in preclinical development for the treatment of psoriasis.